Today’s Stock Alert: Is Selling Stock Like Seres Therapeutics Inc After Such Decline Winning Strategy?

Today's Stock Alert: Is Selling Stock Like Seres Therapeutics Inc After Such Decline Winning Strategy?

The stock of Seres Therapeutics Inc (NASDAQ:MCRB) is a huge mover today! The stock decreased 3.08% or $0.39 during the last trading session, hitting $12.29. About 557,294 shares traded hands. Seres Therapeutics Inc (NASDAQ:MCRB) has declined 46.82% since February 29, 2016 and is downtrending. It has underperformed by 57.24% the S&P500.
The move comes after 5 months negative chart setup for the $475.47 million company. It was reported on Oct, 1 by We have $10.94 PT which if reached, will make NASDAQ:MCRB worth $52.30M less.

Analysts await Seres Therapeutics Inc (NASDAQ:MCRB) to report earnings on November, 8. They expect $-0.51 earnings per share, down 34.21% or $0.13 from last year’s $-0.38 per share. After $-0.70 actual earnings per share reported by Seres Therapeutics Inc for the previous quarter, Wall Street now forecasts -27.14% EPS growth.

Seres Therapeutics Inc (NASDAQ:MCRB) Ratings Coverage

Out of 5 analysts covering Seres Therapeutics Inc (NASDAQ:MCRB), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Seres Therapeutics Inc has been the topic of 12 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The rating was initiated by Leerink Swann on Tuesday, July 21 with “Outperform”. The stock has “Outperform” rating given by Cowen & Co on Monday, June 6. Goldman Sachs initiated the shares of MCRB in a report on Tuesday, July 21 with “Neutral” rating. The stock has “Neutral” rating given by Bank of America on Tuesday, July 21. The company was maintained on Friday, August 12 by FBR Capital. The rating was upgraded by Bank of America on Thursday, October 22 to “Buy”. As per Wednesday, July 22, the company rating was initiated by Canaccord Genuity. Canaccord Genuity maintained Seres Therapeutics Inc (NASDAQ:MCRB) rating on Tuesday, August 25. Canaccord Genuity has “Buy” rating and $50 price target. The firm has “Buy” rating given on Friday, July 29 by H.C. Wainwright. H.C. Wainwright initiated Seres Therapeutics Inc (NASDAQ:MCRB) on Monday, January 25 with “Buy” rating.

According to Zacks Investment Research, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.”

More notable recent Seres Therapeutics Inc (NASDAQ:MCRB) news were published by: which released: “Why Seres Therapeutics Inc. Is Being Obliterated Today” on July 29, 2016, also with their article: “Why Seres Therapeutics Inc. Shares Are Jumping Today” published on August 12, 2016, published: “SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Seres …” on September 28, 2016. More interesting news about Seres Therapeutics Inc (NASDAQ:MCRB) were released by: and their article: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of …” published on September 29, 2016 as well as‘s news article titled: “Seres Therapeutics stock tanks 78% after ‘unexpected’ negative midstage trial …” with publication date: July 29, 2016.

MCRB Company Profile

Seres Therapeutics, Inc., incorporated on October 18, 2010, is a microbiome therapeutics platform company. The Firm is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Firm is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Firm is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI, SER-287 to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens. The Firm is also conducting research on metabolic diseases, such as early-stage, non-insulin dependent diabetes; non-alcoholic steatohepatitis; obesity and metabolic syndrome; other inflammatory diseases, such as Crohn’s disease; cancer chemotherapy and immune suppression; rare genetic diseases, and immune-oncology related applications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment